Abstract
Mucosal vaccine formulations based on purified recombinant C280 gamma-Intimin and EspB (Escherichia coli secreted protein B) from enterohaemorragic E. coli co-administered with a pegylated derivative of the TLR2/6 agonist MALP-2 (macrophage-activating lipopeptide) as adjuvant were evaluated in BALB/c mice. After intranasal vaccination, strong humoral and cellular immune responses were observed against C280 gamma-Intimin and EspB. Sera of immunized mice inhibit bacterial haemolytic activity in vitro. Antigen-specific T-cell proliferation, IL-4, IL-2 and IFN-gamma producing cells, and secretory IgA were mostly detected in animals receiving MALP-2 as adjuvant. These results suggest that C280 gamma-Intimin and EspB are good candidate antigens to be incorporated into mucosal vaccines against this important pathogen.
MeSH terms
-
Adhesins, Bacterial / immunology*
-
Adjuvants, Immunologic*
-
Administration, Intranasal
-
Animals
-
Antibodies, Bacterial / blood
-
Bacterial Outer Membrane Proteins / immunology*
-
Enterohemorrhagic Escherichia coli / immunology*
-
Escherichia coli Infections / immunology
-
Escherichia coli Infections / microbiology
-
Escherichia coli Infections / prevention & control
-
Escherichia coli Proteins / immunology*
-
Escherichia coli Vaccines / administration & dosage*
-
Escherichia coli Vaccines / immunology
-
Female
-
Lipopeptides / immunology*
-
Lymphocyte Activation / immunology
-
Mice
-
Mice, Inbred BALB C
-
T-Lymphocytes / immunology
-
Toll-Like Receptor 2 / agonists
-
Toll-Like Receptor 6 / agonists
-
Vaccination
Substances
-
Adhesins, Bacterial
-
Adjuvants, Immunologic
-
Antibodies, Bacterial
-
Bacterial Outer Membrane Proteins
-
EaeB protein, E coli
-
Escherichia coli Proteins
-
Escherichia coli Vaccines
-
Lipopeptides
-
Tlr2 protein, mouse
-
Tlr6 protein, mouse
-
Toll-Like Receptor 2
-
Toll-Like Receptor 6
-
eaeA protein, E coli
-
macrophage stimulatory lipopeptide 2